Biotron's BIT225 could work in all HCV strains


By Dylan Bushell-Embling
Thursday, 28 November, 2013

Shares in Biotron (ASX:BIT) grew 10% after the company announced independent research suggesting that lead compound BIT225 could be effective across all six major strains of hepatitis C virus (HCV).

A study published in Antiviral Research demonstrates that BIT225, a p7 inhibitor, is active against HCV genotypes 1, 2, 4, 5 and 6 using an in vitro cell culture assay.

Biotron has previously demonstrated that BIT225 is active against genotypes 1 and 3 but has not yet had a chance to trial the compound in patients with other strains of the virus.

“This independent study further validates our plan to progress BIT225 as a new adjunctive therapeutic for Hepatitis C,” Biotron Managing Director Dr Michelle Miller said. “Importantly, this report extends the existing efficacy data and demonstrates that BIT225 has activity across previously untested genotypes.”

Biotron is also developing BIT225 in HIV and earlier this year published research confirming the ability of the compound to target HIV reservoir precursor cells.

The company is also trialling the drug in patients co-infected with both HIV and HCV.

Biotron (ASX:BIT) shares grew 10.13% on Wednesday after the publication of the study was announced. As of around 1.30 pm on Thursday, the shares were trading 1.15% lower at $0.086.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd